About Librede
Librede is a Healthcare company based in San Diego (United States) founded in 2009, and was acquired by Lygos in January 2020. Yeast is engineered via synthetic biology for cannabinoid compound production. Its chief executive, as recorded, is Eric Steen. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Its competitors include Avidity Biosciences, Vividion Therapeutics and Korro Bio; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 2009 in San Diego, United States, Librede operates in the synthetic biology sector focused on drug discovery. Yeast is engineered with metabolic pathways from Cannabis Sativa to produce chemical compounds for the endocannabinoid system, targeting neurodegenerative diseases. Natural and derivative compounds are generated for pharmaceutical and nutraceutical uses, with custom formulations supported. Two products, tetrahydrocannabinol and cannabidiol, are prepared for market launch.
- Headquarters San Diego, United States
- Stage Acquired
- SectorsHealthcare
- Phone•••• ••••
- Website librede.com
- Social LinkedIn
- Acquired by Lygos (Jan 2020)
Funding Insights of Librede
- Total Rounds 8
- Last Round Grant — $224,920
- First Round $907,274
(Sep 2009)
- Investors Count 1
All 8 funding rounds of Librede with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
2 investors in total: 2 institutional.
Investors in Librede
Librede has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Lygos and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Green acids are produced from microbes via synthetic biology. | 2010 | lygos.com | Emeryville, United States |
Investor details for Librede
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Librede
1 people are tracked at Librede (1 in leadership).
| Name | Role | Group |
|---|---|---|
Eric Steen | CEO | Leadership |
Complete people profiles for Librede
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Librede
4 dated milestones of Librede across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Librede is founded.
- Funding First funding round of $907K.
- Funding Latest funding round, Grant, of $225K.
- Exit Acquired by Lygos.
Competitors of Librede
Librede has 3 listed competitors in our database, 3 of them funded. They include Avidity Biosciences, Vividion Therapeutics and Korro Bio.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. |
Detailed competitors of Librede
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Librede (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Librede
Complete news archive for Librede
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Librede
Librede was founded in 2009.
Librede is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Eric Steen is the CEO of Librede, as recorded in our data.
Founded in 2009 in San Diego, United States, Librede operates in the synthetic biology sector focused on drug discovery. Yeast is engineered with metabolic pathways from Cannabis Sativa to produce chemical compounds for the endocannabinoid system, targeting neurodegenerative diseases. Natural and derivative compounds are generated for pharmaceutical and nutraceutical uses, with custom formulations supported. Two products, tetrahydrocannabinol and cannabidiol, are prepared for market launch.
Librede's top competitors include Avidity Biosciences, Vividion Therapeutics and Korro Bio.
Yes. Librede was acquired by Lygos in January 2020.